Season’s Greetings from Team Vaxx Research!

As 2024 comes to a close, we want to take a moment to reflect on a year filled with significant milestones and share the exciting progress we’ve made in our mission to transform HIV prevention and care. At Vaxx, our journey is defined by grit, resilience, focus, and dedication—qualities that have enabled us to achieve extraordinary advancements in a short time.

Our 2024 Highlights:

Strengthening Our Foundation: In September, we filed our first CIPO patent and welcomed top-tier technical leadership, including Dr. George Estafanos as Chief Medical Officer and Dr. Suraj Abraham as Chief Technology Officer. Dr. Estafanos brings expertise in AI and Health care, while Dr. Abraham's expertise in technology integration and extensive expertise in developing end-to-end RNA based therapeutics and vaccine drug products is pivotal in advancing our innovative therapies.

Global Recognition: In November, we were honoured to join the NVIDIA Inception program, a significant milestone that spotlights our efforts in building world-class infrastructure in the GTA to support Vaxx's proprietary AI/ML innovation engine. This platform fuels drug discovery and development in cell and gene therapies focused on our first vertical on HIV prevention and treatment management, which aligns with the 2025 UN Sustainability Goal # 3 on Good Health and Wellness. We are proud to be part of this global initiative.

World-Class Advisors: This December, we welcomed Prof. Michael Gottlieb, the discoverer of AIDS in the 1980s, and Prof. CS Gurumurthy, a pioneer in EasiCRISPR gene-editing technology, to our advisory board. Their guidance, particularly in immunology, cell & gene therapy, genome engineering and virology, propels us forward in cutting-edge research.

Accelerator Program Achievements: Our acceptance into the MaRS, Communitech, and Innovation Factory accelerator programs underscores the strength of our vision and positions us to access transformative resources and our commitment to supporting Canada-based solutions supporting cutting-edge research in AI/ML-based drug discovery and development in the Cell and Gene therapy specifically RNA-based Therapeutics.

Looking Ahead to 2025:

The New Year promises even more significant strides, including expanding our team, finalizing a lead investor who believes in our core values and mission, securing lab resources, and progressing our proprietary HIV mRNA vaccine and adoptive cell therapy modalities toward clinical trials.

A Heartfelt Thank You to our supporters. Your support, collaboration, and belief in our mission have been instrumental in our journey. We deeply appreciate your contributions and look forward to your continued support as we prepare for 2025.

We are deeply grateful for the support, collaboration, and belief from our partners, advisors, and team members who share our vision. As we prepare for 2025, we look forward to forging new partnerships and continuing to push the boundaries of what’s possible in AI/ML based drug development and HIV treatment.

From all of us at Vaxx Research, we wish you and your loved ones a Merry Christmas and a Happy New Year. Let’s make 2025 a year of hope, innovation, and impact together.

Warm regards, 

On behalf of VAXX  

Paul Michael Hallelujah 

CEO & Co-founder

Vaxx Research Inc. | invest@vaxxtx.com | www.vaxxtx.com